| Autor: |
Caputo, Roberta, Buono, Giuseppe, Lauro, Vincenzo Di, Cianniello, Daniela, Arx, Claudia Von, Pensabene, Matilde, Pagliuca, Martina, Pacilio, Carmen, Rella, Francesca Di, Verrazzo, Annarita, Martinelli, Claudia, Nuzzo, Francesco, Laurentiis, Michelino De |
| Zdroj: |
Future Oncology; Aug2023, Vol. 19 Issue 24, p1695-1708, 14p |
| Abstrakt: |
Neratinib is a tyrosine kinase receptor inhibitor used in the extended adjuvant therapy of early-stage breast cancer. After adjuvant trastuzumab therapy, neratinib reduces the risk of recurrence and, if taken within 1 year from trastuzumab, significantly improves the invasive disease-free survival of patients with early-stage human epidermal growth factor receptor-2 positive (HER2+) breast cancer with no increased risk of long-term toxicity. Diarrhea, the most common adverse event associated with neratinib use, deters some clinicians from prescribing this drug. However, neratinib-related toxicity is predictable, short-lived, mostly limited to the first month of treatment and can be managed with dose-escalation and prophylactic strategies. Thus, close surveillance and prompt management, relying on supportive care and administration schedule modification, allows discontinuation of treatment to be avoided. Neratinib, administered within 1 year of trastuzumab, significantly improves disease-free survival in early-stage HER2+ breast cancer, with no increased risk of long-term toxicity. #neratinib #HER2+BC [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
